Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Jiang, Di Maria
Sim, Hao-Wen
Siu, Lillian L.
Shapiro, Jeremy David
Liu, Geoffrey
Price, Timothy Jay
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC)
    Bando, Hideaki
    Oki, Eiji
    Takeda, Yuriko
    Misumi, Toshihiro
    Suzuki, Motoko
    Wakabayashi, Masashi
    Yamazaki, Kentaro
    Grothey, Axel
    Mayer, Robert J.
    Li, Jin
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 115 - 115
  • [32] Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).
    Vincenzi, Bruno
    Loupakis, Fotios
    Bianchi, Andrea Sartore
    Russo, Antonio
    Mannavola, Francesco
    Perrone, Giuseppe
    Cremolini, Chiara
    Rossini, Daniele
    Ongaro, Elena
    Bonazzina, Erica
    Dell'Aquila, Emanuela
    Imperatori, Marco
    De Maglio, Giovanna
    Falcone, Alfredo
    Santini, Daniele
    Onetti-Muda, Andrea
    Siena, Salvatore
    Aprile, Giuseppe
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC)
    Abid, Haisam
    Szabo, Aniko
    Taylor, Bradley W.
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Kamgar, Mandana
    Thomas, James P.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC)
    Kramar, A.
    Paule, B.
    Burtin, P.
    Tougeron, D.
    Desseigne, F.
    Dourthe, L. M.
    Wallet, J.
    Etienne, P. L.
    Mineur, L.
    Becuwe, C.
    Maes, P.
    Dauba, J.
    Michel, P.
    Hollebecque, A.
    Linot, B.
    Morere, J. F.
    De la Fouchardiere, C.
    Phelip, J. M.
    Andre, T.
    Adenis, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S358 - S358
  • [35] Baseline absolute neutrophil counts (ANC) and survival in second- line metastatic colorectal cancer (mCRC) patients (pts).
    Grothey, Axel
    Tabernero, Josep
    Mytelka, Daniel S.
    Li, Li
    Nasroulah, Federico
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [36] Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).
    Vatandoust, Sina
    Roy, Amitesh Chandra
    Price, Timothy Jay
    Ullah, Shahid
    Beeke, Carol
    Townsend, Amanda Rose
    Padbury, Rob
    Roder, David
    Maddern, Guy
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score
    Gresham, Gillian
    Cheung, Winson Y.
    Chan, Matthew
    Kim, Jason
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [38] Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score
    Chen, Leo
    Gresham, Gillian
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study
    Mathias, C. de Cerqueira
    Perazzo, F.
    Simon, S.
    Fein, L.
    Hidalgo, J.
    Murad, A. M.
    Lerzo, G.
    Esser, R.
    Scheid, S.
    Buzaid, A. C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 252 - 253
  • [40] Cetuximab plus bevacizumab in patients (pts) with metastatic colorectal cancer (mCRC) who have failed on irinotecan, oxaliplatin and fluoropyrimidines-based chemotherapy
    Souglakos, J.
    Kalbakis, K.
    Vamvakas, N.
    Kalykaki, A.
    Kotsakis, A.
    Agelaki, S.
    Karampeazis, A.
    Gioulbasanis, J.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345